At first, engaging in advocacy initiatives involving government bodies, officials, drug agencies, and various stakeholders invested in improving the healthcare system or treatment accessibility may appear abstract or a little daunting. Nevertheless, numerous organizations, such as ours, are inherently suited to negotiate, influence and persuade those who have the authority to enact changes.

Myeloma Canada has always taken an active stance in advocating for patients’ rights, as well as those of their families,
with proven expertise and success.

In recent years, myeloma has been the focus of many research projects, coinciding with major shifts within our healthcare system. As such, Myeloma Canada regularly finds itself at the epicentre of crucial discussions poised to directly shape the future of our community and impact all Canadians affected by cancer. Our initiatives span a range of issues, aiming to improve prevention, early diagnosis, access to the best treatments, and to the best services available.

In 2023, to solidify our efforts, we reconvened the Myeloma Canada National Advocacy Committee (NAC), recruited new members, and established a new structure for the committee.

Find out more here